Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

Switching from natalizumab to fingolimod: an observational study

(2013) A. P. Sempere et al.   ACTA NEUROLOGICA SCANDINAVICA

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

(2012) Anke Stroet et al.   Therapeutic Advances in Neurological Disorders

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

(2011) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

(2011) E Le Page et al.   Multiple Sclerosis Journal

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

(2011) V. Martinelli et al.   NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY

Concepts of induction and escalation therapy in multiple sclerosis

(2009) Peter Rieckmann   JOURNAL OF THE NEUROLOGICAL SCIENCES

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Induction vs. escalating therapy in Multiple Sclerosis: practical implications

(2008) Giancarlo Comi   NEUROLOGICAL SCIENCES

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

(2007) E. Le Page et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY